Nearly half of employers that track condition-specific data cite cancer as the No. 1 contributor to higher healthcare expenses, according to the 2025 Brown & Brown Employer Health and Benefits Strategy Survey.
Advancements in the precision and effectiveness of cancer treatments and medications come at a higher price point. While these improvements hold clinical promise, they are also driving up costs. Yet with proactive evaluation and effective strategies, your employer clients can strike a balance between managing the bottom line and ensuring access to high-quality cancer care.
